Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC

  • STATUS
    Recruiting
  • End date
    Dec 25, 2023
  • participants needed
    292
  • sponsor
    Biocad
Updated on 25 January 2021

Summary

This is a randomized, multicenter, double-blind placebo-controlled phase 3 study of efficacy and safety of BCD-100 in combination with pemetrexed+cisplatin/carboplatin compared to placebo in combination with pemetrexed+cisplatin/carboplatin in subjects with previously untreated metastatic non-squamous NSCLC. The main hypothesis of the study is that BCD-100 in combination with chemotherapy prolongs OS compared to placebo with chemotherapy.

Details
Condition Non-Squamous Non-Small Cell Neoplasm of Lung, Non-Squamous Non-Small Cell Neoplasm of Lung, Non-Squamous Non-Small Cell Neoplasm of Lung
Treatment Placebo, Pemetrexed, BCD-100, Cisplatin (or carboplatin)
Clinical Study IdentifierNCT03912389
SponsorBiocad
Last Modified on25 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have Non-Squamous Non-Small Cell Neoplasm of Lung?
Do you have any of these conditions: Do you have Non-Squamous Non-Small Cell Neoplasm of Lung??
Subject has voluntarily agreed to participate by giving written informed consent for the trial
Patients 18 years of age on day of signing informed consent
Previously untreated patients with histologically-confirmed stage IV (M1a/M1b/M1cAJCC 8th edition) non-squamous NSCLC
Has not received prior systemic treatment for metastatic NSCLC
The time from the completion of previous adjuvant/neoadjuvant treatment to metastatic disease development is no less than 12 months
Has a life expectancy of at least 12 weeks
Has Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Has adequate organ function as defined by hematological laboratory values (absolute neutrophil count 1.500/mcL, platelets 100.000/mcL, hemoglobin 9 g/dL ), renal laboratory values (serum creatinine or calculated creatinine clearance <1.5xULN or 60 mL/min for subjects with creatinine levels>1.5x institutional ULN), and hepatic laboratory values (serum total bilirubin <1.5xULN, AST and ALT 2.5xULN, alkaline phosphatase <2.5xULN)
Agreement to newly obtained core or excisional biopsy of a tumor lesion not previously irradiated for determination of PD-L1 status prior to randomization (if obtaining of new sample is contraindicated or puts subject at unacceptable risks, then archival tumor tissue sample must be available)
Measurable disease according to CT scan (RECIST 1.1 criteria) , confirmed by the local assessment
For subjects of childbearing potential: agreement to remain abstinent (refrain from heterosexual inter-course) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 6 months after administration of the last dose of study drug; and 6 months after the last dose of platinum-based chemotherapy, whichever is later. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state ( 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries, fallopian tubes, and/or uterus). Examples of contraceptive methods with a failure rate of < 1% per year include but are not limited to bilateral tubal ligation and/or occlusion, male sterilization, and intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception

Exclusion Criteria

Has predominantly squamous cell histology NSCLC; Mixed tumors will be categorized by the predominant cell type; if small cell elements are present, the subject is ineligible
Presence of EGFR mutation or ALK translocation
Has received prior systemic cytotoxic chemotherapy/chemoradiotherapy for metastatic disease
Has received antineoplastic therapy with targeted or immunotherapeutic drugs (including but not limited to EGFR inhibitors [e.g., erlotinib, gefitinib, cetuximab], ALK inhibitors, PD-1/PD-L1/PD-L2/CTLA4, VEGF/VEGFR inhibitors) or it is expected to require any other form of antineoplastic therapy while on study
Completed radiation therapy within 14 days before the first dose of the study drug
Received a live-virus vaccination within 30 days prior to the first study drug administration
Current treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study
Had major surgery less than 28 days prior to the first dose of the study drug
Evidence of severe or concomitant diseases/life-threatening complications of the main condition (including but not limited to massive pleural, pericardial, or peritoneal effusion that requires medical intervention , pulmonary lymphangitis, hemorrhage, organ perforation) at the signing of the informed consent
Concomitant diseases or conditions which pose a risk of AE development during study
treatment
uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm Hg; define diagnosis of hypertension
stable angina functional class III-IV
unstable angina or myocardial infarction less than 6 months prior to randomization
NYHA Grade III-IV congestive heart failure
serious cardiac arrhythmia requiring medication (subjects with asymptomatic atrial fibrillation can be enrolled if controlled ventricular rate)
atopic asthma, Stage III-IV COPD, angioedema
severe respiratory failure
any other diseases which pose unacceptable risk of AE development during study treatment in Investigator's opinion
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Active or known or suspected autoimmune disease (subjects with Type 1 diabetes mellitus, hypothyroidism only requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll)
Has clinically active diverticulitis, intra-abdominal abscess, GI obstruction, abdominal carcinomatosis
Has interstitial lung disease or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management. Lymphangitic spread of the NSCLC is not exclusionary
Condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications in past 2 years
Is unable or unwilling to take folic acid or vitamin B12 supplementation
Known history of prior malignancy except if participant has undergone potentially curative therapy with no evidence of that disease recurrence for 2 years since initiation of that therapy, except for successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers
Pre-existing clinically significant ( grade 2) peripheral neuropathy or hearing impairment
Any conditions or circumstances that limit subject's ability to comply with protocol requirements
Active hepatitis B, hepatitis or HIV in anamnesis
Acute infection or reactivation of chronic infection or systemic antibiotics use less than 14 days prior to first dose of the study drug; Severe infections within 28 days prior to the first study drug administration
Significant adverse reactions of previous therapy excluding chronic and/or irreversible events which cannot affect study drug safety evaluation (e.g. alopecia)
Known hypersensitivity or allergy to drugs containing Chinese hamster (CHO) ovary cells or history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins, to pemetrexed, carboplatin, cisplatin, BCD-100 or any of their excipients
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note